| 35 | Humans |
| 16 | Antibodies, Monoclonal, Humanized (therapeutic use) |
| 10 | Pandemics |
| 10 | Female |
| 8 | Pneumonia, Viral (drug therapy) |
| 8 | Coronavirus Infections (drug therapy) |
| 8 | Betacoronavirus |
| 8 | Antibodies, Monoclonal, Humanized |
| 7 | Middle Aged |
| 7 | Male |
| 6 | Interleukin-6 (antagonists & inhibitors) |
| 6 | Adult |
| 5 | Treatment Outcome |
| 5 | Antirheumatic Agents (therapeutic use) |
| 4 | Pneumonia, Viral (complications) |
| 4 | Double-Blind Method |
| 4 | Disease Progression |
| 4 | Coronavirus Infections (complications) |
| 3 | Takayasu Arteritis (drug therapy) |
| 3 | Receptors, Interleukin-6 (immunology) |
| 3 | Pneumonia, Viral (immunology) |
| 3 | Interleukin-6 (metabolism) |
| 3 | Interleukin-6 (blood) |
| 3 | Immunosuppressive Agents (therapeutic use) |
| 3 | Giant Cell Arteritis (drug therapy) |
| 3 | Coronavirus Infections (immunology) |
| 3 | Arthritis, Rheumatoid (drug therapy) |
| 3 | Antibodies, Monoclonal, Humanized (adverse effects) |
| 3 | Antibodies, Monoclonal, Humanized (administration & dosage) |
| 3 | Aged |
| 2 | Turkey |
| 2 | Sulfonamides (therapeutic use) |
| 2 | Still's Disease, Adult-Onset |
| 2 | Retrospective Studies |
| 2 | Receptors, Interleukin-6 (metabolism) |
| 2 | Receptors, Interleukin-6 (antagonists & inhibitors) |
| 2 | Randomized Controlled Trials as Topic |
| 2 | Proportional Hazards Models |
| 2 | Molecular Targeted Therapy |
| 2 | Methotrexate (therapeutic use) |
| 2 | Japan |
| 2 | Hydroxychloroquine (therapeutic use) |
| 2 | Glucocorticoids |
| 2 | Glucocorticoids (therapeutic use) |
| 2 | Giant Cell Arteritis (diagnostic imaging) |
| 2 | Follow-Up Studies |
| 2 | Cytokines (immunology) |
| 2 | Cytokine Release Syndrome |
| 2 | Coronavirus Infections (therapy) |
| 2 | Chloroquine (therapeutic use) |
| 2 | Cell Movement (drug effects) |
| 2 | Betacoronavirus (drug effects) |
| 2 | Azetidines (therapeutic use) |
| 2 | Aortitis (drug therapy) |
| 2 | Antibodies, Monoclonal, Humanized (pharmacology) |
| 2 | Alanine (therapeutic use) |
| 2 | Alanine (analogs & derivatives) |
| 2 | Adenosine Monophosphate (therapeutic use) |
| 2 | Adenosine Monophosphate (analogs & derivatives) |
| 1 | World Health Organization |
| 1 | Vitamin D (therapeutic use) |
| 1 | Vitamin D (blood) |
| 1 | Vitamin D (analogs & derivatives) |
| 1 | Virus Internalization (drug effects) |
| 1 | Vasculitis (drug therapy) |
| 1 | Uncertainty |
| 1 | Ultrasonography |
| 1 | Tumor Necrosis Factor Inhibitors (therapeutic use) |
| 1 | Transplantation, Homologous |
| 1 | Tomography, X-Ray Computed |
| 1 | Tocilizumab |
| 1 | Thrombocytopenia |
| 1 | Takayasu Arteritis |
| 1 | Takayasu Arteritis (physiopathology) |
| 1 | Takayasu Arteritis (pathology) |
| 1 | Takayasu Arteritis (etiology) |
| 1 | Takayasu Arteritis (diagnostic imaging) |
| 1 | Takayasu Arteritis (diagnosis) |
| 1 | Takayasu Arteritis (complications) |
| 1 | Takayasu Arteritis (blood) |
| 1 | T-Lymphocytes (immunology) |
| 1 | T-Lymphocytes (drug effects) |
| 1 | Synovial Membrane (physiopathology) |
| 1 | Synovial Membrane (immunology) |
| 1 | Synovial Membrane (drug effects) |
| 1 | Stroke (epidemiology) |
| 1 | Steroids (therapeutic use) |
| 1 | Steroids (pharmacology) |
| 1 | Steroids (adverse effects) |
| 1 | Steroids (administration & dosage) |
| 1 | Sjogren's Syndrome (drug therapy) |
| 1 | Signal Transduction |
| 1 | Signal Transduction (drug effects) |
| 1 | Severity of Illness Index |
| 1 | Sepsis (etiology) |
| 1 | Secondary Prevention (methods) |
| 1 | Scleroderma, Systemic |
| 1 | Scleroderma, Systemic (drug therapy) |
| 1 | Scleroderma, Systemic (complications) |
| 1 | Salvage Therapy (methods) |
| 1 | STAT3 Transcription Factor (metabolism) |
| 1 | STAT Transcription Factors (metabolism) |
| 1 | STAT Transcription Factors (antagonists & inhibitors) |
| 1 | Ruxolitinib |
| 1 | Rituximab (therapeutic use) |
| 1 | Ritonavir (therapeutic use) |
| 1 | Risk Factors |
| 1 | Rheumatology |
| 1 | Rheumatic Diseases (therapy) |
| 1 | Rheumatic Diseases (complications) |
| 1 | Respiratory Distress Syndrome, Adult |
| 1 | Republic of Korea (epidemiology) |
| 1 | Registries (statistics & numerical data) |
| 1 | Recurrence |
| 1 | Receptors, Interleukin-6 (genetics) |
| 1 | Prospective Studies |
| 1 | Prognosis |
| 1 | Practice Guidelines as Topic |
| 1 | Positron Emission Tomography Computed Tomography |
| 1 | Pneumonia, Viral |
| 1 | Pneumonia, Viral (therapy) |
| 1 | Pneumonia, Viral (prevention & control) |
| 1 | Pneumonia, Viral (physiopathology) |
| 1 | Pneumonia, Viral (pathology) |
| 1 | Pneumonia, Viral (mortality) |
| 1 | Pneumonia, Viral (etiology) |
| 1 | Pneumonia, Viral (epidemiology) |
| 1 | Pneumonia, Viral (diagnostic imaging) |
| 1 | Plant Preparations (therapeutic use) |
| 1 | Phytotherapy |
| 1 | Physicians (psychology) |
| 1 | Phosphorylation (drug effects) |
| 1 | Patient Selection |
| 1 | Patient Care Team |
| 1 | Pandemics (prevention & control) |
| 1 | Ovarian Neoplasms (pathology) |
| 1 | Ovarian Neoplasms (metabolism) |
| 1 | Ovarian Neoplasms (genetics) |
| 1 | Osteogenesis (drug effects) |
| 1 | Neuraminidase (antagonists & inhibitors) |
| 1 | Neoplasms (therapy) |
| 1 | Neoplasms (immunology) |
| 1 | Neoplasms (complications) |
| 1 | Myositis (drug therapy) |
| 1 | Myocardial Infarction (epidemiology) |
| 1 | Multiple Myeloma (drug therapy) |
| 1 | Multiple Myeloma (complications) |
| 1 | Monitoring, Physiologic (methods) |
| 1 | Macrophages (immunology) |
| 1 | Macrophages (drug effects) |
| 1 | Lymphohistiocytosis, Hemophagocytic |
| 1 | Lung |
| 1 | Lung Neoplasms (therapy) |
| 1 | Lung Neoplasms (diagnosis) |
| 1 | Lung Neoplasms (complications) |
| 1 | Lopinavir (therapeutic use) |
| 1 | Leukocytes, Mononuclear |
| 1 | Leg |
| 1 | Janus Kinases (metabolism) |
| 1 | Janus Kinases (antagonists & inhibitors) |
| 1 | Janus Kinase Inhibitors (therapeutic use) |
| 1 | JAK inhibition |
| 1 | Italy (epidemiology) |
| 1 | Intermittent Claudication (etiology) |
| 1 | Interleukin-8 (metabolism) |
| 1 | Interleukin-8 (drug effects) |
| 1 | Interleukin-6 |
| 1 | Interleukin-6 (pharmacology) |
| 1 | Interleukin-6 (immunology) |
| 1 | Interleukin-6 (genetics) |
| 1 | Interleukin-1 (antagonists & inhibitors) |
| 1 | Interleukin 6 |
| 1 | Intercellular Adhesion Molecule-1 (metabolism) |
| 1 | Intercellular Adhesion Molecule-1 (drug effects) |
| 1 | Inflammation Mediators (metabolism) |
| 1 | Inflammation Mediators (antagonists & inhibitors) |
| 1 | Inflammation (metabolism) |
| 1 | Inflammation (enzymology) |
| 1 | Inflammation (drug therapy) |
| 1 | Immunotherapy (adverse effects) |
| 1 | Immunosuppressive Agents (pharmacology) |
| 1 | Immunosuppression |
| 1 | Immunomodulation |
| 1 | Immunization, Passive |
| 1 | Idiopathic Pulmonary Fibrosis |
| 1 | IL-6 |
| 1 | IL-6 receptor |
| 1 | Hypertension (physiopathology) |
| 1 | Hypertension (etiology) |
| 1 | Hepatic inflammation |
| 1 | Hematopoietic Stem Cell Transplantation (adverse effects) |
| 1 | Graves Ophthalmopathy (metabolism) |
| 1 | Graves Ophthalmopathy (immunology) |
| 1 | Graves Ophthalmopathy (drug therapy) |
| 1 | Graft vs Host Disease (etiology) |
| 1 | Graft vs Host Disease (drug therapy) |
| 1 | Glucocorticoids (administration & dosage) |
| 1 | Giant Cell Arteritis (pathology) |
| 1 | Gene Expression Regulation, Neoplastic (drug effects) |
| 1 | Gastrointestinal Agents (adverse effects) |
| 1 | Gastrointestinal Agents (administration & dosage) |
| 1 | Fibroblasts (metabolism) |
| 1 | Fibroblasts (immunology) |
| 1 | Fibroblasts (drug effects) |
| 1 | Fever |
| 1 | Femoral Artery (physiopathology) |
| 1 | Femoral Artery (diagnostic imaging) |
| 1 | Fatal Outcome |
| 1 | Familial Mediterranean Fever (drug therapy) |
| 1 | Etanercept |
| 1 | Etanercept (therapeutic use) |
| 1 | Endothelial Cells (immunology) |
| 1 | Endothelial Cells (drug effects) |
| 1 | Edema |
| 1 | Dyspnea (etiology) |
| 1 | Drugs, Investigational (pharmacology) |
| 1 | Drugs, Investigational (adverse effects) |
| 1 | Drug Therapy, Combination |
| 1 | Drug Repositioning |
| 1 | Drug Development |
| 1 | Drug Combinations |
| 1 | Disease Management |
| 1 | Cytokines (genetics) |
| 1 | Critical Illness |
| 1 | Cough (etiology) |
| 1 | Coronavirus Infections |
| 1 | Coronavirus Infections (prevention & control) |
| 1 | Coronavirus Infections (physiopathology) |
| 1 | Coronavirus Infections (pathology) |
| 1 | Coronavirus Infections (mortality) |
| 1 | Coronavirus Infections (etiology) |
| 1 | Coronavirus Infections (epidemiology) |
| 1 | Coronavirus Infections (diagnostic imaging) |
| 1 | Constriction, Pathologic (etiology) |
| 1 | Connective Tissue Diseases (drug therapy) |
| 1 | Combined Modality Therapy |
| 1 | Colonoscopy |
| 1 | Colitis, Ulcerative (immunology) |
| 1 | Colitis, Ulcerative (genetics) |
| 1 | Colitis, Ulcerative (drug therapy) |
| 1 | Colitis, Ulcerative (diagnosis) |
| 1 | Colchicine (therapeutic use) |
| 1 | Clinical Trials, Phase II as Topic |
| 1 | Clinical Trials as Topic |
| 1 | Clinical Trials as Topic (methods) |
| 1 | Clinical Protocols (standards) |
| 1 | Clinical Decision-Making |
| 1 | Chronic Disease |
| 1 | Child |
| 1 | Chemokines |
| 1 | Chemokines (metabolism) |
| 1 | Chemokines (drug effects) |
| 1 | Chemokine CCL2 (metabolism) |
| 1 | Chemokine CCL2 (drug effects) |
| 1 | Cells, Cultured |
| 1 | Cell Survival (drug effects) |
| 1 | Cell Proliferation (drug effects) |
| 1 | Cell Movement (immunology) |
| 1 | Cell Line |
| 1 | Cell Line, Tumor |
| 1 | Cell Adhesion (immunology) |
| 1 | Cell Adhesion (drug effects) |
| 1 | Castleman Disease |
| 1 | Cardiovascular Diseases (mortality) |
| 1 | Carcinoma, Large Cell (therapy) |
| 1 | Carcinoma, Large Cell (diagnosis) |
| 1 | Carcinoma, Large Cell (complications) |
| 1 | Cachexia (drug therapy) |
| 1 | Cachexia (diagnosis) |
| 1 | Cachexia (complications) |
| 1 | C-reactive protein |
| 1 | C-Reactive Protein (drug effects) |
| 1 | Biopsy |
| 1 | Biomarkers (blood) |
| 1 | Biological Therapy |
| 1 | Betacoronavirus (pathogenicity) |
| 1 | Betacoronavirus (isolation & purification) |
| 1 | Betacoronavirus (immunology) |
| 1 | Azithromycin (therapeutic use) |
| 1 | Autoimmune Diseases (therapy) |
| 1 | Autoimmune Diseases (complications) |
| 1 | Arthritis, Rheumatoid |
| 1 | Arthritis, Rheumatoid (epidemiology) |
| 1 | Arthritis, Rheumatoid (complications) |
| 1 | Arthritis (physiopathology) |
| 1 | Arthritis (immunology) |
| 1 | Arthritis (drug therapy) |
| 1 | Aortitis (pathology) |
| 1 | Aortitis (diagnostic imaging) |
| 1 | Aortitis (diagnosis) |
| 1 | Aortitis (blood) |
| 1 | Aorta, Thoracic (diagnostic imaging) |
| 1 | Antiviral Agents (therapeutic use) |
| 1 | Antirheumatic Agents (adverse effects) |
| 1 | Antineoplastic Combined Chemotherapy Protocols (therapeutic use) |
| 1 | Antineoplastic Agents (therapeutic use) |
| 1 | Antineoplastic Agents (pharmacology) |
| 1 | Antineoplastic Agents (adverse effects) |
| 1 | Antimalarials (therapeutic use) |
| 1 | Antibodies, Monoclonal, Humanized (immunology) |
| 1 | Antibodies, Monoclonal (therapeutic use) |
| 1 | Antibodies, Monoclonal (pharmacology) |
| 1 | Anti-Inflammatory Agents, Non-Steroidal (therapeutic use) |
| 1 | Anti-Inflammatory Agents (therapeutic use) |
| 1 | Anti-Inflammatory Agents (adverse effects) |
| 1 | Anti-Inflammatory Agents (administration & dosage) |
| 1 | Animals |
| 1 | Angiotensin-Converting Enzyme Inhibitors (therapeutic use) |
| 1 | Angiotensin Receptor Antagonists (therapeutic use) |
| 1 | Adrenal Cortex Hormones (adverse effects) |
| 1 | Adolescent |
| 1 | Adhesion molecules |
| 1 | Adenocarcinoma, Clear Cell (pathology) |
| 1 | Adenocarcinoma, Clear Cell (metabolism) |
| 1 | Adenocarcinoma, Clear Cell (genetics) |
| 1 | Acute Coronary Syndrome (prevention & control) |
| 1 | Acute Coronary Syndrome (physiopathology) |
| 1 | Acute Coronary Syndrome (drug therapy) |
| 1 | Abatacept (therapeutic use) |
